



Malaria: Current Opportunities in Therapeutics and Vaccines

Guest Editor:

Dr. Anita Cohen

UMR IRD 257 VITROME, Aix-
Marseille Université, IHU
Méditerranée Infection, 19-21
Boulevard Jean Moulin, 13005
Marseille, France

Deadline for manuscript
submissions:

closed (30 May 2023)

Message from the Guest Editor

Malaria remains one of the most important public health problems and currently shows stagnant progress, causing an estimated 229,000 cases and 409,000 deaths worldwide in 2019, according to the latest World Health Organization (WHO) World Malaria Report. In a context of increasing (multi)drug resistance, the recent WHO recommendation for widespread use of the RTS,S/AS01 (RTS,S) malaria vaccine in children in sub-Saharan Africa and other areas with moderate to high *P. falciparum* malaria transmission was declared to be " a breakthrough for science, child health, and malaria control" by WHO Director-General Dr T. A. Ghebreyesus.

I would like to invite colleagues who are studying any aspect of malaria treatment, whether preventive or curative, to submit their preclinical/clinical developments or feedback on their use from a public health perspective to this Special Issue. All types of articles will be considered for publication, including short reports, original research articles, and reviews.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Lawrence S. Young

Warwick Medical School,
University of Warwick, Coventry
CV4 7AL, UK

Message from the Editor-in-Chief

The worldwide impact of infectious disease is incalculable. The consequences for human health in terms of morbidity and mortality are obvious and vast but, when infections of animals and plants are also taken into account, it is hard to imagine any other disease that has such a significant impact on our lives—on healthcare systems, on agriculture and on world economics. *Pathogens* is proud to continue to serve the international community by publishing high quality studies that further our understanding of infection and have meaningful consequences for disease intervention.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PubAg, CaPlus / SciFinder, AGRIS, and other databases.

Journal Rank: JCR - Q2 (*Microbiology*) / CiteScore - Q2 (*General Immunology and Microbiology*)

Contact Us

Pathogens Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pathogens
pathogens@mdpi.com
[X@Pathogens_MDPI](https://twitter.com/Pathogens_MDPI)